Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results
Open Access
- 1 November 2015
- journal article
- Published by Elsevier in European Urology
- Vol. 68 (5) , 787-794
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate CancerEuropean Urology, 2014
- FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide™)Molecular and Cellular Endocrinology, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- The patient's choice of androgen‐deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin‐releasing hormone analogue or orchidectomyBJU International, 2005
- BICALUTAMIDE 150 MG MAINTAINS BONE MINERAL DENSITY DURING MONOTHERAPY FOR LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCERJournal of Urology, 2004
- Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancerUrology, 2003
- BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUPJournal of Urology, 2000
- Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancerClinical Endocrinology, 1994